Analysis Advanced BioMedical Technologies, Inc. (ABMT)
5/29/2024
Analysis of Advanced BioMedical Technologies, Inc. (ABMT)
Advanced BioMedical Technologies, Inc. (ABMT) has been trading at a consistent price of 0.00060 over the past few days. The Relative Strength Index (RSI) indicator is showing a value of 30.32202, indicating that the stock may be oversold.Looking at the Moving Average Convergence Divergence (MACD) indicator, we see that the MACD line is below the signal line, with a value of -0.00101. However, the MACD histogram is showing a positive value of 0.00043, suggesting a potential bullish momentum.
In terms of moving averages, the Simple Moving Average (SMA) is at 0.00060, while the Exponential Moving Average (EMA) is at 0.00221. This indicates that the stock has been trading below its long-term average.
Overall, based on the RSI, MACD, and moving averages, it seems that Advanced BioMedical Technologies, Inc. may be in oversold territory with a potential for a bullish reversal in the near future. However, further analysis and confirmation from other technical indicators would be recommended before making any trading decisions.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the near term compared to the past performance. However, the company is still projected to experience healthy growth over the next few years according to analyst consensus.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price is below both the average and median forecast, indicating that there is potential for growth according to the analysts' predictions.
Earnings
The company's results for the latest quarter ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results from October 31, 2024, were not provided at the time. On August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a relatively low short ratio and a significant percentage of shares held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.
Valuation metrics show a high PEG ratio and price-to-book ratio, indicating potentially overvalued stock. The company's market capitalization and enterprise value are substantial, with moderate price-to-sales and enterprise-to-EBITDA ratios.
The stock price summary includes beta, moving averages, and the range of prices over the past year. Dividends and splits data show the company's dividend history, payout ratio, and dividend yield metrics.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, indicating efficient cost control measures.
4. Operating income has shown an increasing trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been on the rise, reaching $97 billion in 2023 from $57.4 billion in 2020.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally increased over the years.
7. The company has been able to maintain a healthy EBITDA margin, indicating strong operational performance.
8. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving over the years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
6. The company has been relying more on non-current assets to support its operations.
7. There has been a consistent increase in shareholders' equity, indicating a positive trend in the company's financial health.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, with a range from $1.27 to $1.36. This shows growth compared to the EPS of $1.26 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, with a range from $1.44 to $1.63. This indicates an increase compared to the EPS of $1.46 from the same quarter a year ago.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.59, with a range from $6.43 to $6.92. This reflects growth compared to the EPS of $6.13 from the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average EPS estimate is $7.23, with a range from $6.40 to $7.90. This suggests an increase compared to the EPS of $6.59 from the previous fiscal year.
Overall, the analysts are forecasting growth in earnings per share for both the upcoming quarters and the full fiscal years, indicating positive expectations for the company's performance.
MACD of ABMT
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
